Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering

Positive

AI Analysis

Summary

Arrowhead Pharmaceuticals is acquiring a Priority Review Voucher (PRV) for $215M, representing the highest PRV price this year. Twist Bioscience plans to raise $300M through a public offering.

Outcome Details

Arrowhead Pharmaceuticals acquiring PRV for $215M

Importance:6/10

Sentiment:

0.30

M&AacquisitionPRVpublic offeringcapital raise

Related Companies

$TWST

Read the original article

Published by Endpoints News on August 5, 2026 2:28 PM

Read Original